Dedicated to Discovery. Committed to Care.

Turning Point

The cover's checkerboard design is inspired by "gene chip" technology, which identifies cancer cells by their distinct pattern, or "signature," of gene activity. The women are patients in the Women's Cancers Program.

The cover's checkerboard design is inspired by "gene chip" technology, which identifies cancer cells by their distinct pattern, or "signature," of gene activity. The women are patients in the Women's Cancers Program.

Fall/Winter 2005

Contents

Credits

Turning Point is published for supporters of Dana-Farber's Women's Cancers Program. To learn more about the WCP, call Administrative Director Candace S. Lowe, ScD, at (617) 632-2675.
Comments, suggestions, and requests to be added to or deleted from the mailing list may be sent to:

Turning Point
Dana-Farber Cancer Institute
Department of Communications
44 Binney Street, OS300
Boston, MA 02115

or call (617) 632-4090
or e-mail: TurningPoint@dfci.harvard.edu

EDITOR: Dawn Stapleton
ASSOCIATE EDITOR: Richard Saltus
SCIENCE ADVISORS: Ian Krop, MD, PhD; Jennifer Ligibel, MD
ART DIRECTOR: John DiGianni
DESIGN: Kimberly Regensburg
CONTRIBUTORS: Robert Levy
PRODUCTION COORDINATOR: Jeff Cleary
PHOTOGRAPHY: C.J. Allen, Shawn Henry, Bill Horsman, Matthew McKee

Turning Point Archive
E-mail this page

History of advances

From achieving the first remissions of ALL and Wilm's tumor in pediatric patients in the '40s and '50s, to the development of Gleevec, the first "smart" cancer drug, in the late '90s, Dana-Farber researchers and clinicians have been at the forefront of discovery in cancer care and research. learn more